Compare Vaxcyte Inc. Common Stock (PCVX) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Skyworks Solutions Inc — how do they compare? Vaxcyte Inc. Common Stock trades at $67.75 (market cap $10.63B), while Skyworks Solutions Inc trades at $77.25 (market cap $18.08B). The key difference: Skyworks Solutions Inc is the larger of the two by market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Skyworks Solutions Inc for 50 Days on average.
| PCVX | SWKS | |
|---|---|---|
Market Cap | $10.63B | $18.08B |
Volume | 1,525,205 | 5,128,915 |
Sector | Health | Technology |
52-Week High | $73.82 | $91.45 |
52-Week Low | $40.32 | $52.50 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $9.26B | $17.96B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Skyworks Solutions (SWKS) trades at $76.56, up 2.49% today, with a bearish technical signal but positive analyst sentiment. The stock has beaten EPS estimates for the last three quarters, though revenue and net income have trended lower since 2022. The pending merger with Qorvo is a key catalyst, expected to close soon and generate significant synergies. Valuation ratios like P/E of 39.84 and P/S of 2.88 reflect market expectations for growth post-merger.
The outlook is mixed: merger benefits offer upside, but execution risks and declining profitability pose challenges. Analysts are largely bullish with a $79.70 consensus target, suggesting modest upside. Investors should weigh merger synergies against integration risks and current financial trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
